BTIG analyst Mark Massaro lowered the firm’s price target on GeneDx (WGS) to $170 from $200 but keeps a Buy rating on the shares after its Q4 earning beat. The company has wrapped up a successful 2025 and is making big investments to the business in 2026 going after large new market opportunities, the analyst tells investors in a research note. BTIG adds it is positive on the fundamentals of the business and new opportunities ahead for the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx: Solid Execution, Structural Growth Drivers, and Undervalued Long‑Term Opportunity Support Buy Rating
- GeneDx price target lowered to $130 from $160 at Piper Sandler
- Genedx Holdings Warned of Potential Goodwill and Intangible Asset Impairments That Could Hit Earnings
- GeneDx: Attractive Entry Point on Rebased Valuation and Robust 2026 Growth Outlook
- GeneDx price target lowered to $150 from $180 at Jefferies